Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Theodoros Vassilakopoulos, Javier Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Miguel Bergua Burgues, Ou Bai, Alejandro Berkovits, Keshu Zhou, Marc Hoffmann, Jason Westin, Maria Bouzani, Michal Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz Nowakowski
Institutions: National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Sun Yat-sen University Cancer Center, University of Yamanashi, Dong-A University, Hospital San Pedro de Alcántara, First Hospital of Jilin University, First Bethune Hospital of Jilin University, Zhengzhou University, University of Kansas Medical Center, The University of Texas MD Anderson Cancer Center, Evangelismos Hospital, Poznan University of Medical Sciences, National Taiwan University Hospital, Bristol-Myers Squibb (Switzerland), Bristol-Myers Squibb (United States), Mayo Clinic
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417012121
Cites:
Cited by:
Related to: